Fig. 3.

Propensity-score-weighted hazard ratios for composite CV event during as-treated follow-up period: Secondary comparisons. CI confidence interval, CV cardiovascular, DRV darunavir, HR hazard ratio, PI protease inhibitor

Propensity-score-weighted hazard ratios for composite CV event during as-treated follow-up period: Secondary comparisons. CI confidence interval, CV cardiovascular, DRV darunavir, HR hazard ratio, PI protease inhibitor